Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Fishman

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Cancer Research|April 6, 2007
Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancerMeera Nanjundan, Yasuhisa Nakayama, Kwai Wa Cheng, et al.
Oncotarget|December 23, 2015
NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanismsHailing Yang, Partha Das, Yinhua Yu, et al.
Nature Medicine|October 27, 2004
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancersKwai Wa Cheng, John P Lahad, Wen-Lin Kuo, et al.
Molecular & Cellular Proteomics : MCP|January 27, 2005
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinomaKatherine M Sheehan, Valerie S Calvert, Elaine W Kay, et al.
Cancer Research|June 4, 2009
Biological significance of prolactin in gynecologic cancersVera V Levina, Brian Nolen, YunYun Su, et al.
Clinical Chemistry|August 16, 2005
Analysis of albumin-associated peptides and proteins from ovarian cancer patientsMark S Lowenthal, Arpita I Mehta, Kristina Frogale, et al.
Biophotonics Discovery|April 24, 2026
Improved endoscope for imaging and cell collection in the fallopian tubesDominique Gálvez, Andrew Daniel Rocha, Alana G Gonzales, et al.
Cancer Causes & Control : CCC|August 30, 2003
Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States)Francesmary Modugno, Roxana Moslehi, Roberta B Ness, et al.
Proteomics|October 24, 2007
Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post-translational modificationsChenwei Liu, Nancy Shea, Sally Rucker, et al.
American Journal of Obstetrics and Gynecology|March 29, 2025
Digital tool for genetic cancer risk assessment in a historically underserved population: a randomized controlled trialEmily M Webster, Muhammad Danyal Ahsan, Isabelle R Chandler, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Cancer Research|April 6, 2007
Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancerMeera Nanjundan, Yasuhisa Nakayama, Kwai Wa Cheng, et al.
Oncotarget|December 23, 2015
NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanismsHailing Yang, Partha Das, Yinhua Yu, et al.
Nature Medicine|October 27, 2004
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancersKwai Wa Cheng, John P Lahad, Wen-Lin Kuo, et al.
Molecular & Cellular Proteomics : MCP|January 27, 2005
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinomaKatherine M Sheehan, Valerie S Calvert, Elaine W Kay, et al.
Cancer Research|June 4, 2009
Biological significance of prolactin in gynecologic cancersVera V Levina, Brian Nolen, YunYun Su, et al.
Clinical Chemistry|August 16, 2005
Analysis of albumin-associated peptides and proteins from ovarian cancer patientsMark S Lowenthal, Arpita I Mehta, Kristina Frogale, et al.
Biophotonics Discovery|April 24, 2026
Improved endoscope for imaging and cell collection in the fallopian tubesDominique Gálvez, Andrew Daniel Rocha, Alana G Gonzales, et al.
Cancer Causes & Control : CCC|August 30, 2003
Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States)Francesmary Modugno, Roxana Moslehi, Roberta B Ness, et al.
Proteomics|October 24, 2007
Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post-translational modificationsChenwei Liu, Nancy Shea, Sally Rucker, et al.
American Journal of Obstetrics and Gynecology|March 29, 2025
Digital tool for genetic cancer risk assessment in a historically underserved population: a randomized controlled trialEmily M Webster, Muhammad Danyal Ahsan, Isabelle R Chandler, et al.
Pageof 4